Bridgeway Capital Management’s Immunomedics Inc IMMU Stock Holding History

Bridgeway Capital Management’s Portfolio IMMU Stock Details IMMU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-188,900	Closed	-$1.22M	–	1494
2017 Q1	$1.22M	Sell	188,900 -100,000	-35%	-$507K	0.01%	741
2016 Q4	$1.06M	Hold	288,900	–	–	0.01%	800
2016 Q3	$939K	Hold	288,900	–	–	0.01%	825
2016 Q2	$670K	Hold	288,900	–	–	0.01%	931
2016 Q1	$722K	Hold	288,900	–	–	0.01%	907
2015 Q4	$887K	Hold	288,900	–	–	0.02%	813
2015 Q3	$497K	Buy	288,900 +66,000	+30%	+$168K	0.01%	1032
2015 Q2	$905K	Sell	222,900 -2,400	-1%	-$9.81K	0.02%	828
2015 Q1	$863K	Hold	225,300	–	–	0.02%	848
2014 Q4	$1.08M	Hold	225,300	–	–	0.02%	741
2014 Q3	$838K	Hold	225,300	–	–	0.02%	828
2014 Q2	$822K	Hold	225,300	–	–	0.02%	857
2014 Q1	$949K	Hold	225,300	–	–	0.03%	783
2013 Q4	$1.04M	Sell	225,300 -26,000	-10%	-$116K	0.03%	725
2013 Q3	$1.56M	Sell	251,300 -12,800	-5%	-$73.7K	0.05%	520
2013 Q2	$1.44M	Buy	+264,100	New	+$867K	0.06%	476

Other funds holding IMMU

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Bridgeway Capital Management's IMMU Position: Q2 2017 in Review

Bridgeway Capital Management sold out of Immunomedics Inc (IMMU) in Q2 2017, closing a stake of 188,900 shares — an estimated $1.22M sold.

Bridgeway Capital Management first reported a position in IMMU in Q2 2013 and held it in 16 quarters. The position peaked at $1.56M in Q3 2013. 130 funds tracked by Wall St. Rank hold IMMU as of Q2 2017.

Bridgeway Capital Management reported no remaining Immunomedics Inc position as of Q2 2017 after selling out during the quarter.
Bridgeway Capital Management sold 188,900 Immunomedics Inc shares in Q2 2017, an estimated $1.22M.
Bridgeway Capital Management first reported a position in Immunomedics Inc in Q2 2013 and held it in 16 quarters.
Bridgeway Capital Management's Immunomedics Inc position peaked at $1.56M in Q3 2013.
130 funds tracked by Wall St. Rank held Immunomedics Inc as of Q2 2017.

Based on Bridgeway Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.